ArticleHuman vaccines & immunotherapeutics2025
A post-marketing safety surveillance study on vaccines in Chongqing, China from 2006 to 2021: Using a nationwide spontaneous reporting database with multiple data mining methods.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Update on Selected Adverse Events of Concern Following Immunization With Acellular Pertussis Vaccines, a Narrative Review.Acta paediatrica (Oslo, Norway : 1992) · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Chinese National Adverse Events Following Immunization Information System (CNAEFIS) is the national-level passive vaccine safety surveillance system. This study aims to identify post-marketing vaccine adverse reaction signals in Chongqing through systematic analysis of 15-year AEFI data, verify the safety profile of locally recommended vaccines, and provide localized evidence for clinical practice and immunization policy formulation. The study included all 36 marketed vaccines in mainland China and collected all rare adverse reactions (RAR) reported in Chongqing through CNAEFIS from 2006 to 2021. Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayes Gamma-Poisson Shrinker (GPS) were employed to mine potential safety signals within the database. From 2006 to 2021, approximately 90.1 million vaccine doses were recorded in Chongqing, China, and 20,195 individual cases of Adverse Events Following Immunization (AEFIs) were reported. Of these, 3,110 cases (15.4%) were linked to RAR, at an incidence rate of 32.2 per 100,000 doses. Allergic reactions were the most prevalent, with 2,743 cases (88.2% of the RAR), and the Measles-Rubella Vaccine (MR) had the highest IR of allergic reactions, reaching 267.1 cases per 100,000 doses administered. A total of 23 suspicious signals were identified through the combined use of PRR, ROR, GPS, and BCPNN methods. The corresponding clinical diagnoses were mainly non-serious diseases such as angioedema, Henoch-Schönlein purpura, and local abscess. The warning signals of severe diseases such as anaphylactic shock and laryngeal edema, which could be life-threatening due to improper clinical treatment, were weak. The overall safety of vaccines in Chongqing is satisfactory. Vaccine manufacturers should optimize the production process to enhance vaccine tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.